Benzinga | Nov 11, 2021 07:55AM EST

Credit Suisse Maintains Outperform on Ascendis Pharma, Lowers Price Target to $179

Credit Suisse analyst Tiago Fauth maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and lowers the price target from $185 to $179.